topical drug delivery
| 3 min read
Phase 2 trial shows that a topical drug rapidly reduces malodor, pain, and improves quality of life for patients with malignant fungating wounds.
| 2 min read
EXN407 is the first topical SRPK1 inhibitor to demonstrate safety and efficacy as a monotherapy for non-proliferative diabetic retinopathy (NPDR) and diabetic macular oedema.
| 2 min read
Dermaliq’s proprietary hyliQ® technology platform enables touchless delivery of novel drug therapies to fragile, sensitive or disease-affected skin.
| 3 min read
Researchers investigated the feasibility of microbiome-based drug delivery as a longer-lasting alternative to current topical formulations.
Page 1 of 1 - 4 Total Items
